<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588939</url>
  </required_header>
  <id_info>
    <org_study_id>07-006186</org_study_id>
    <nct_id>NCT00588939</nct_id>
  </id_info>
  <brief_title>Confocal Laser Microscopy in Non Erosive Reflux Disease</brief_title>
  <official_title>Confocal Laser Microscopy in Non Erosive Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heartburn or reflux disease affects about 20% of Americans. 50 - 70% of people who have&#xD;
      endoscopy for reflux disease have a normal appearing esophagus. Confocal Laser Microscopy&#xD;
      allows us to see changes in the cells not visable during routine endoscopy. Whe goal of this&#xD;
      study is to identify the use of this new technique in diagnosing reflux in patients who have&#xD;
      normal appearing esophagus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroesophageal reflux disease (GERD) remains a major problem in the United States affecting&#xD;
      about 20% of Americans. Upper endoscopy (EGD) is commonly used to diagnose and grade GERD&#xD;
      based on mucosal breaks and erosions. It is now evident from multiple studies however that&#xD;
      the majority of GERD patients (50-70%) have negative EGDs.These patients are refered to as&#xD;
      &quot;Non Erosive Reflux Disease&quot; (NERD) patients.Confocal Laser Microscopy (CLM) is a new&#xD;
      endoscopic technique that offers the advantage of detecting histologic changes during real&#xD;
      time endoscopy and thus can diagnose NERD. We thus propose to study the sensitivity and&#xD;
      specificity of CLM in predicting NERD. We hypothesize that CLM can reliably diagnose NERD in&#xD;
      the appropriate clinical setting based on intrapapillary capillary loop patterns. This will&#xD;
      be a pilot study after which a randomized trial will evaluate the reversibility of these&#xD;
      changes after PPI therapy as seen by CLM&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the sensitivity, specificity, negative and positive predictive value of CLM in diagnosing NERD</measure>
    <time_frame>at time of procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the additional charges of implementing CLM in EGD</measure>
    <time_frame>at time of procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Acid Reflux Disease</condition>
  <condition>Heartburn</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <description>participants with symptoms of acid reflux disease (heartburn)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cell~vizio (Laser connfocal microscopy)</intervention_name>
    <description>completed during endoscopy</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Mauna Kea Cellvizeo</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      esophageal biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        age 18 - 65 years symptoms of acid reflux disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years to 85 years old who are referred for an upper endoscopy for symptoms&#xD;
             of reflux disease&#xD;
&#xD;
          2. Patients who are able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of Erosive esophagitis&#xD;
&#xD;
          2. Patients with a history of Barrett's esophagus&#xD;
&#xD;
          3. Patients who on upper endoscopy have any current evidence of erosive esophagitis,&#xD;
             Barrett's esophagus or varices&#xD;
&#xD;
          4. Patients who are unable or unwilling to undergo endoscopic evaluation&#xD;
&#xD;
          5. Patients who are unable to give informed consent&#xD;
&#xD;
          6. Patients with a known coagulopathy who are unable to be off therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth K Wang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rami Badreddine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malyo Clinic Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mayoresearch.mayo.edu/mayo/research/wang_lab/</url>
    <description>Barrett's Esophagus Research Unit</description>
  </link>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>December 22, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2008</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kenneth K. Wang</investigator_full_name>
    <investigator_title>VanCleve Professor of Gastroenterology Research</investigator_title>
  </responsible_party>
  <keyword>reflux</keyword>
  <keyword>heartburn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

